News releases from Acorda Therapeutics, Inc.
Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance and 2016/2017 Clinical Milestones at J.P. Morgan Healthcare Conference
January 10, 2016
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2015 of $121 million. Unaudited 2015...
Acorda Presents Analyses on Use of Healthcare Services for Seizure Clusters at American Epilepsy Society Annual Meeting
December 07, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced analyses from a study showing the effect of rescue medication for seizure clusters on both clinical outcomes and healthcare resource utilization....
Acorda Initiates Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines
December 02, 2015
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of...
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Oppenheimer Healthcare Conference in New York on Tuesday, December 8 at 11:30 am.
Acorda Therapeutics to Present at Two Investor Conferences in November
November 09, 2015
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during November.
Acorda Provides Financial and Pipeline Update for 2015 Third Quarter
October 21, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today provided a financial and pipeline update for the third quarter ended September 30, 2015.
Acorda Therapeutics to Host Conference Call to Discuss Third Quarter Results on October 22, 2015
October 08, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a conference call and webcast to report its third quarter 2015 financial results and pipeline updates on Thursday, October 22 at 8:30...
Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
October 07, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of pharmacokinetic data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple...
Acorda Recognized with Legal Media Group 2015 Life Sciences Award
October 02, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that its legal team has been recognized with a Legal Media Group 2015 Life Sciences Award as a “Hatch-Waxman Impact Case of the Year.” Acorda...
Acorda Named One of the 100 Best Workplaces for Women by Fortune and Great Place to Work
September 30, 2015
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100 Best Workplaces for Women based on an independent survey by Fortune and Great Place to Work®. The survey included more than...
Acorda Presents Data on Inhaled Levodopa Therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders
June 16, 2015
Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 05, 2015
Acorda Reports First Quarter 2015 Financial Results
April 29, 2015
Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results on April 30, 2015
April 23, 2015
Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting
April 22, 2015
Acorda Rings NASDAQ Opening Bell to Mark 20th Anniversary
March 16, 2015
Acorda to Present New Analyses of Cimaglermin alfa (GGF2) Data at the 64th Annual ACC Scientific Session
March 10, 2015
Acorda Therapeutics to Present at the 2015 RBC Capital Markets’ Healthcare Conference
February 16, 2015
Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2014 Financial Results on February 12, 2015
February 04, 2015
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis
February 01, 2015